Vnitr Lek 2015, 61(12):1016-1022

Antithrombotic therapy and nonvariceal upper gastrointestinal bleeding

Veronika Belanová1,*, Martin Gřiva2
1 Oddělení intenzivní péče operačních oborů Krajské nemocnice T. Bati, a.s., Zlín, vedoucí pracoviště prim. MUDr. Anna Šobáňová
2 Kardiocentrum pro dospělé Interní kliniky Krajské nemocnice T. Bati, a.s., Zlín, vedoucí pracoviště prim. MUDr. Jiří Latta

Background:
The incidence of acute upper gastrointestinal bleeding is about 85-108/100,000 inhabitants per year, nonvariceal bleeding accounts for 80-90 %. Antiplatelet and anticoagulation treatment are the significant risk factors for upper gastrointestinal bleeding.

Objectives:
To evaluate the occurrence of upper gastrointestinal bleeding in the general community of patients in a county hospital. And to compare the role played by antiplatelet and anticoagulation drugs and other risk medication.


Design and methods:
Retrospective analysis of patients over 18 years of age who underwent endoscopy for acute upper gastrointestinal bleeding or anaemia (haemoglobin < 100 g/l) with proved source of blood losses in upper gastrointestinal tract during a hospital stay in 2013 (from January to June).

Results:
We included 111 patients of average age 69 ± 15 years, men 60 %. Nonvariceal bleeding accounted for 90 % of the cases. None of the patients with variceal bleeding (10 % of patients) took antiplatelet or anticoagulation therapy. There were 100 patients with nonvariceal bleeding of average age 70 ± 15, 61 % men. With the symptoms of acute bleeding (hematemesis, melena) presented in 73 % of patients. The most frequent cause of bleeding was gastric and duodenal ulcer (54 %). 32 % of patients with nonvariceal bleeding had antiplatelets, 19 % anticoagulants and 10 % used nonsteroidal anti-inflammatory drugs, selective serotonin reuptake inhibitors or corticosteroids. 30-days mortality of patients with nonvariceal bleeding was 11 %, annual mortality was 23 %. There was no significant difference in mortality, blood transfusion requirements or surgical intervention between the patients with antithrombotic agents and without them. 25 % of patients (8 patients) using acetylsalicylic acid did not fulfil the indication for this treatment.

Conclusion:
Among the patients examined by endoscopy for symptomatic nonvariceal bleeding and/or anaemia (haemoglobin < 100 g/l) significantly higher portions of patients are taking antiplatelet rather than anticoagulation therapy. This may be caused by greater use of these drugs in the population, but on the other hand it may reflect an association with greater risk of gastrointestinal bleeding. With regard to that, it is alarming, that there still exists a nonnegligible percentage of patients taking acetylsalicylic acid even though they do not meet the indication for the prescription according to the guidelines.

Keywords: antiplatelet therapy and anticoagulation; upper gastrointestinal bleeding

Received: April 13, 2015; Accepted: July 28, 2015; Published: December 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Belanová V, Gřiva M. Antithrombotic therapy and nonvariceal upper gastrointestinal bleeding. Vnitr Lek. 2015;61(12):1016-1022.
Download citation

References

  1. Crooks C, West J, Card T. Upper gastrointestinal haemorrhage and deprivation: a nationwide cohort study of health inequality in hospital admissions. Gut 2012; 61(4): 514-520. Go to original source... Go to PubMed...
  2. Paspatis GA, Konstantinidis K, Chalkiadakis I et al. Changing trends in acute upper gastrointestinal bleeding in Crete, Greece: a population-based study. Eur J Gastroneterol Hepatol 2012; 24(1): 102-103. Go to original source... Go to PubMed...
  3. Loperfido S, Baldo V, Piovesana E at al. Changing trends in acute upper-GI bleeding: a population-based study. Gastrointest endosc 2009; 70(2): 212-224. Go to original source... Go to PubMed...
  4. Theocharis GJ, Thomopoulos KC, Sakellaropoulos G et al. Changing trends in the epidemiology and clinical outcome of acute upper gastrointestinal bleeding in a defined geographical area in Greece. J Clin Gastroenterol 2008; 42(2): 128-133. Go to original source... Go to PubMed...
  5. Palmer K. Acute upper gastrointestinal heamorrhage. Br Med Bull 2007; 83: 307-324. Go to original source... Go to PubMed...
  6. Van Leerdam ME, Vreeburg EM, Rauws EAJ et al. Acute Upper GI Bleeding: Did Anything Change?, Time Trend Analysis of Incidence and Outcome of Acute Upper GI Bleeding Between 1993/1994 and 2000. Am J Gastroenterol 2003; 98(7): 1494-1499. Go to original source... Go to PubMed...
  7. Esrailian E, Gralenk IM. Nonvariceal Upper Gastrointestinal Bleeding: Epidemiology and Diagnosis. Gastroenterol Clin North Am 2005; 34(4): 589-605. Go to original source... Go to PubMed...
  8. Tariq SH, Mekhijan G. Gastrointestinal Bleeding in Older Adults. Clin Geriatr Med 2007; 23(4): 769-784. Go to original source... Go to PubMed...
  9. Hearnshaw SA, Logan RF, Lowe D et al. Acute upper gastrointestinal bleeding in the UK: patient characteristics, diagnoses and outcomes in the 2007 UK audit. Gut 2011; 60(10): 1327-1335. Go to original source... Go to PubMed...
  10. Di Fiore F, Lecleire S, Merle V et al. Changes in characteristics and outcome of acute upper gastrointestinal haemorrhage: a comparison of epidemiology and prectices between 1996 and 2000 in a multicentre French study. Eur J Gastroenterol Hepatol 2005; 17(6): 641-647. Go to original source... Go to PubMed...
  11. Hallas J, Dall M, Andries A et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ 2006; 333(7571): 726. Go to original source... Go to PubMed...
  12. Delaney JA, Opatrny L, Brophy JM et al. Drug-drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ 2007; 177(4): 347-351. Go to original source... Go to PubMed...
  13. Lanas A, García-Rodríguez LA, Arroyo MT et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006; 55(12): 1731-1738. Go to original source... Go to PubMed...
  14. Hreinsson JP, Kalaitzakis E, Gudmundsson S et al. Upper gastrointestinal bleeding: incidence, etiology and outcomes in a population-based setting. Scand J Gastroenterol 2013; 48(4): 439-447. Go to original source...
  15. Loke YK, Trivedi AN, Singh S. Meta-analysis: gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2008; 27(1): 31-40. Go to original source... Go to PubMed...
  16. Dall M, Schaffalitzky de Muckadell OB, Lassen AT et al. An association between selective serotonin reuptake inhibitor use and serious upper gastrointestinal bleeding. Clin Gastroenterol Hepatol 2009; 7(12): 1314-1321. Go to original source... Go to PubMed...
  17. Åhsberg K, Höglund P, Kim WH et al. Impact of aspirin, NSAIDs, warfarin, corticosteroids and SSRIs on the site and outcome of non-variceal upper and lower gastrointestinal bleeding. Scand J Gastroenterol 2010; 45(12): 1404-1415. Go to original source... Go to PubMed...
  18. Thomopoulos KC, Vagenas KA, Vagianos CE et al. Changes in aetiology and clinical outcome of acute upper gastrointestinal bleeding during the last 15years. Eur J Gastroneterol Hepatol 2004; 16(2): 177-182. Go to original source... Go to PubMed...
  19. Pisters R, Lane DA, Nieuwlaat H et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138(5): 1093-1100. Go to original source... Go to PubMed...
  20. Roldán V, Marín F, Fernández H et al. Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a "real-world" population with atrial fibrillation receiving anticoagulant therapy. Chest 2013; 143(1): 179-184. Go to original source... Go to PubMed...
  21. Caldeira D, Costa J, Fernandes RM et al. Performance of the HAS-BLED high bleeding-risk category, compared to ATRIA and HEMORR2HAGES in patients with atrial fibrillation: a systematic review and meta-analysis. J Interv Card Electrophysiol 2014; 40(3): 277-284. Go to original source... Go to PubMed...
  22. Lip GYH, Frison L, Halperin JL et al. Comparative Validation of a Novel Risk Score for Predicting Bleeding Risk in Anticoagulated Patients with Atrial Fibrillation. J Am Coll Cardiol 2011; 57(2): 173-180. Go to original source... Go to PubMed...
  23. Morales-Uribe CH, Sierra-Sierra S, Hernándéz-Hernández AM et al. Upper gastrointestinal bleeding: risk factors for mortality in two urban centers in Latin America. Rev Esp Enferm Dig 2001; 103(1): 20-24. Go to original source...
  24. Barkun A, Sabbah S, Enns R et al. The Canadian Registry on Nonvariceal Upper Gastrointestinal Bleeding and Endoscopy (RUGBE): endoscopic hemostasis and proton pump inhinition are associated with improved outcomes in a real-life setting. Am J Gastroenterol 2004; 99(7): 1238-1246. Go to original source... Go to PubMed...
  25. Hnízdil L, Piskač P, Dvořák M et al. Akutní endoskopické řešení krvácení do horní části gastrointestinálního traktu: zkušenosti jednadvaceti let. Prakt Lék 2011; 91(7): 404-408.
  26. Bureš J, Kopáčová M, Škodová Fendrichová M et al. Epidemiologie Helicobacter pylori. Vnitř Lék 2011; 57(12): 993-999. Go to PubMed...
  27. Bureš J, Kopáčová M, Koupil I et al. Significant decrease in prevalence of Helicobacter pylori in the Czech Republic. World J Gastroenterol 2012; 18(32): 4412-4418. Go to original source...
  28. Kopacova M, Koupil I, Seifert B et al. Blood pressure and stature in Helicobacter pylori positive and negative persons. World J Gastroenterol 2014; 20(19): 5625-5631. Go to original source... Go to PubMed...
  29. Wikman-Jorgensen P, Lopéz-Calleja E, Safont-Gasó P et al. Antiagregation and anticoagulation, relationship with upper gastrointestinal bleeding. Rev Esp Enferm Dig 2011; 103(7): 360-365. Go to original source... Go to PubMed...
  30. Perk J, De Backer G, Gohlke H et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 33(13): 1635-1701. Erratum in Eur Heart J 2012; 33(17):2126. Go to original source... Go to PubMed...
  31. Camm AJ, Lip GYH, De Caterina R et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33(21): 2719-2747. Erratum in Eur Heart J 2013; 34(10): 790. Eur Heart J 2013; 34(36): 2850-2851. Go to original source...
  32. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34(28): 2159-2219. Go to original source... Go to PubMed...
  33. Penka M, Schwarz J, Campr V et al. Shrnutí doporučení České pracovní skupiny pro Ph-negativní myeloproliferativní onemocnění (CZEMP) České hematologické společnosti ČLS JEP pro diagnózu a terapii BCR/ABL-negativních myeloproliferací. Vnitř Lék 2012; 58(2): 163-168. Go to PubMed...
  34. Lukáš M, Špičák J, Keil R. Doporučení České gastroenterologické společnosti pro podávání antiagregační terapie kyselinou acetylsalicylovou. Gastroent Hepatol 2013; 67(2): 90-94.
  35. Bureš J, Dítě P, Fixa B et al. Infekce Helicobacter pylori. Doporučený postup České gastroenterologické společnosti ČSL JEP pro dospělé. Gastroent Hepatol 2013; XX-XX (Guidelines): 1-5. Dostupné z WWW: <http://www.cgs-cls.cz/wp-content/uploads/2015/04/guidelines-infekce-helicobacter-pylori.pdf>.
  36. Konečný M, Ehrmann J, Procházka V et al. Naše zkušenosti s novou organizací péče o nemocné s akutním krvácením do horní části trávicího traktu. Vnitř Lék 2005; 51(1): 36-40.




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.